Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Weight-loss drugs like Wegovy and On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S's (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep sedation surgery.
欧洲药品管理局（EMA）周五警告服用减肥药物（例如诺和诺德A / S（NYSE：NVO）的Wegovy）的患者，在进行全身麻醉或深度镇静手术之前告知医生。
This recommendation stems from potential respiratory complications linked to these medications.
这项建议源于与这些药物相关的呼吸并发症的潜在风险。
Related: Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.
相关:研究显示，只有25%的患者在服用了诺和诺德公司的维戈维或欧秦匹克两年后继续使用；公司称数据不足。
Weight-loss drugs like Wegovy and Eli Lilly And Co's (NYSE:LLY) Zepbound and Mounjaro belong to a class known as GLP-1 receptor agonists, which slow the emptying of food from the stomach, making users feel full for longer periods.
Wegovy和礼来（Eli Lilly And Co）的Zepbound和Mounjaro等减肥药属于叫做GLP-1受体激动剂的药物类别，减缓胃部排空，使用户感觉更长时间的饱。
Their action of slowing gastric emptying is already noted in the product information for various drugs in this class, such as dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide.
它们减缓胃的排空作用在该类药物的各种药品信息中已经得到注意，例如dulaglutide，exenatide，liraglutide，lixisenatide，semaglutide和tirzepatide。
The EMA's drug safety committee, PRAC, highlighted the risk of aspiration, a condition where stomach contents might move into the respiratory tract, potentially causing pneumonia.
EMA的药品安全委员会PRAC强调了吸入风险问题，即胃内容物可能移入呼吸道，从而可能导致肺炎。
This risk is particularly concerning for patients undergoing anesthesia or deep sedation during surgery. Although the regulator has not established a definitive causal link between GLP-1 drugs and aspiration, the nature of these medications' action on delaying gastric emptying presents a plausible risk.
对于在手术过程中接受麻醉或深度镇静的患者，这种风险特别令人担忧。尽管监管机构尚未确定GLP-1药物和吸入性风险之间的确切因果关系，但这些药物通过延迟胃排空的作用，可能存在一种合理的风险。
The PRAC reviewed data from various sources, including case reports from EudraVigilance, scientific literature, and clinical trials. Despite the inability to confirm a direct association between GLP-1 analogs and aspiration, the committee emphasized the importance of awareness among healthcare professionals and patients regarding the potential risks.
PRAC从EudraVigilance的病例报告，科学文献和临床试验等各种来源中审核了数据。尽管无法确认GLP-1类似物与吸入之间的直接关联，但委员会强调了医疗保健专业人员和患者对潜在风险的重视。
Aspiration and pneumonia aspiration complicate between one in 900 to one in 10,000 general anesthesia procedures, depending on risk factors.
吸入性和肺炎性吸入并发症发生在每900到10,000次全身麻醉手术中间，这取决于风险因素。
Price Action: NVO shares are up 2.02% at $142.62, and LLY shares are up 0.97% at $943.24 at the last check on Friday.
截至周五最后一次检查，NVO股票上涨2.02％至142.62美元，LLY股票上涨0.97％至943.24美元。
- Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds.
- 研究发现，诺和诺德的“奇迹”减肥药物Ozempic与48％的较低痴呆症风险相关。
Photo by Ciara Kimsey via Shutterstock
照片来自Shutterstock
